• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Express Scripts, other PBMs named in lawsuit over pricey EpiPens

August 31, 2017 By Sarah Faulkner

GavelExpress Scripts (NSDQ:ESRX) and other pharmacy benefit managers have been accused of giving Mylan‘s (NSDQ:MYL) EpiPens favorable placement on drug formularies in exchange for kickbacks, according to a proposed class action filed in Kansas federal court this week.

The suit was brought by people covered under Employee Retirement Income Security Act benefit plans. These consumers claim that pharmacy benefit managers breached their fiduciary duties under the Employee Retirement Income Security Act of 1974, alleging that drugmakers like Mylan hike the price of EpiPens and other devices to give a portion of the profit back to PBMs, who in turn give them preferential placement on drug formularies.

PBMs can direct business to the drugmakers that pay the highest rebate, the consumers reportedly said, since they represent thousands of people on healthcare plans.

“While PBMs could use this market power to drive down the prices for medical products by forcing manufacturers to lower the list price, instead they and manufacturers have figured out a way to game the system for their mutual benefit,” the complaint said, according to Law360.

“Defendants obtain large payments from the manufacturers in exchange for granting access to the exclusionary formularies, increasing the PBM take, and manufacturers like Mylan pay rebates without diminishing — and, at times, even increasing — their profits because their net profits are protected by the ever-increasing list prices, and sales are ensured through formulary placement.”

Express Scripts’ VP of corporate communication told Law360 that the suit has “absolutely no merit” and that the company plans to “vigorously” defend itself.

Mylan has come under fire in the last year after reports revealed that the company raised the price of its EpiPen product by more than 500% over the past decade. Mylan has since launched a generic version of its emergency allergy device, which sells at $300 per two-pack – a 50% discount on the price of its EpiPen device.

In August, Express Scripts announced that it would include Mylan’s EpiPen emergency allergy device on its 2018 formulary, favoring the drugmaker’s product over auto-injectors from competitors like Impax Laboratories (NSDQ:IPXL)  and Kaleo.

The largest pharmacy benefit manager in the U.S. has practiced excluding certain medicines from its list of covered drugs since 2014, pointing towards the high prices taken on by health insurers.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Express Scripts, Mylan

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS